BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38287343)

  • 1. Use of corticosteroids in Norwegian patients with immunoglobulin a nephropathy progressing to end-stage kidney disease: a retrospective cohort study.
    Rivedal M; Haaskjold YL; Eikrem Ø; Bjørneklett R; Marti HP; Knoop T
    BMC Nephrol; 2024 Jan; 25(1):42. PubMed ID: 38287343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroids pulse therapy and oral corticosteroids therapy for IgA nephropathy patients with advanced chronic kidney disease: results of a multicenter, large-scale, long-term observational cohort study.
    Tsunoda R; Usui J; Hoshino J; Fujii T; Suzuki S; Takaichi K; Ubara Y; Yamagata K
    BMC Nephrol; 2018 Sep; 19(1):222. PubMed ID: 30189860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria.
    Pei G; Tan J; Tang Y; Tan L; Zhong Z; Zhou L; Chen C; Qin W
    Medicine (Baltimore); 2020 Jun; 99(24):e20513. PubMed ID: 32541473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C; Torres DD; Rossini M; Pesce F; Schena FP
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic effect of immunosuppressive therapy in IgA nephropathy with stage 3 or 4 chronic kidney disease.
    Yang X; Ma F; Bai M; Wang Y; Jia Q; Dong R; Liu C; Sun S
    Ren Fail; 2021 Aug; 43(1):1180-1187. PubMed ID: 34376108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of corticosteroid therapy for IgA nephropathy patients stratified by kidney function and proteinuria.
    Nagasawa Y; Yamamoto R; Shinzawa M; Shoji T; Hasuike Y; Nagatoya K; Yamauchi A; Hayashi T; Kuragano T; Moriyama T; Isaka Y
    Clin Exp Nephrol; 2020 Oct; 24(10):927-934. PubMed ID: 32642919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria.
    Zhong Z; Tang Y; Tan J; Tan L; Pei G; Qin W
    Int Urol Nephrol; 2021 Jan; 53(1):121-127. PubMed ID: 32944888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppressive agents for treating IgA nephropathy.
    Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
    Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corticosteroid in IgA nephropathy with moderate proteinuria: A retrospective cohort study.
    Wang Y; Yu J; Jiang Y; Li J; Yimamuyushan A; Xia X; Fan L; Huang F; Chen W; Liu Q
    Nephrology (Carlton); 2024 May; 29(5):268-277. PubMed ID: 38186010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroid therapy in IgA nephropathy with minimal proteinuria and high renal pathological score: A single‑center cohort study.
    Tang Y; He H; Sun W; Hu P; Chen X; Xu X
    Mol Med Rep; 2018 Oct; 18(4):4103-4112. PubMed ID: 30132546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy.
    Sarcina C; Tinelli C; Ferrario F; Pani A; De Silvestri A; Scaini P; Del Vecchio L; Alberghini E; Buzzi L; Baragetti I; Pozzi C
    Clin J Am Soc Nephrol; 2016 Jun; 11(6):973-981. PubMed ID: 27129712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Immunosuppressive Treatment May Improve Short-Term Renal Outcomes in Chinese Patients with Advanced IgA Nephropathy.
    Tan L; Tang Y; Peng W; Mathew BS; Qin W
    Kidney Blood Press Res; 2018; 43(4):1333-1343. PubMed ID: 30099439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of corticosteroids in immunoglobulin A nephropathy with less than 25% crescents.
    Chen J; Xu H; Peng Z; Lin L; Li C; Zhu X; Liu S
    Clin Exp Nephrol; 2020 Jan; 24(1):73-81. PubMed ID: 31605314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.
    Coppo R; Lofaro D; Camilla RR; Bellur S; Cattran D; Cook HT; Roberts IS; Peruzzi L; Amore A; Emma F; Fuiano L; Berg U; Topaloglu R; Bilginer Y; Gesualdo L; Polci R; Mizerska-Wasiak M; Caliskan Y; Lundberg S; Cancarini G; Geddes C; Wetzels J; Wiecek A; Durlik M; Cusinato S; Rollino C; Maggio M; Praga M; K Smerud H; Tesar V; Maixnerova D; Barratt J; Papalia T; Bonofiglio R; Mazzucco G; Giannakakis C; Soderberg M; Orhan D; Di Palma AM; Maldyk J; Ozluk Y; Sudelin B; Tardanico R; Kipgen D; Steenbergen E; Karkoszka H; Perkowska-Ptasinska A; Ferrario F; Gutierrez E; Honsova E
    Pediatr Nephrol; 2017 Jan; 32(1):139-150. PubMed ID: 27557557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S; Li JP
    Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study.
    Tesar V; Troyanov S; Bellur S; Verhave JC; Cook HT; Feehally J; Roberts IS; Cattran D; Coppo R;
    J Am Soc Nephrol; 2015 Sep; 26(9):2248-58. PubMed ID: 25677392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of proteinuria by therapeutic intervention improves the renal outcome of elderly patients with IgA nephropathy.
    Okabayashi Y; Tsuboi N; Haruhara K; Kanzaki G; Koike K; Shimizu A; Miyazaki Y; Ohno I; Kawamura T; Ogura M; Yokoo T
    Clin Exp Nephrol; 2016 Dec; 20(6):910-917. PubMed ID: 26830548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic kidney disease progression to end stage renal disease: a single center experience of the role of the underlying kidney disease.
    Ekart R; Ferjuc A; Furman B; Gerjevič Š; Bevc S; Hojs R
    Ther Apher Dial; 2013 Aug; 17(4):363-7. PubMed ID: 23931872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppressive agents for treating IgA nephropathy.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.
    Rauen T; Fitzner C; Eitner F; Sommerer C; Zeier M; Otte B; Panzer U; Peters H; Benck U; Mertens PR; Kuhlmann U; Witzke O; Gross O; Vielhauer V; Mann JFE; Hilgers RD; Floege J
    J Am Soc Nephrol; 2018 Jan; 29(1):317-325. PubMed ID: 29042456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.